The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults

Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely d...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	A. S. Kolbin [verfasserIn] A. A. Kurilev [verfasserIn] Y. E. Balikina [verfasserIn] M. A. Proskurin [verfasserIn]

Format:	E-Artikel
Sprache:	Russisch

Erschienen:	2022

Schlagwörter:	сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений

Übergeordnetes Werk:	In: Качественная клиническая практика - Izdatelstvo OKI, 2020, (2022), 1, Seite 4-16
Übergeordnetes Werk:	year:2022 ; number:1 ; pages:4-16

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.37489/2588-0519-2022-1-4-16

Katalog-ID:	DOAJ097193356

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ097193356
003	DE-627
005	20240413174536.0
007	cr uuu---uuuuu
008	240413s2022 xx \|\|\|\|\|o 00\| \|\|rus c
024	7		\|a 10.37489/2588-0519-2022-1-4-16 \|2 doi
035			\|a (DE-627)DOAJ097193356
035			\|a (DE-599)DOAJ864afcbe094147a9beab69ad5e267701
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a rus
050		0	\|a R855-855.5
050		0	\|a RS1-441
100	0		\|a A. S. Kolbin \|e verfasserin \|4 aut
245	1	4	\|a The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.
650		4	\|a сахарный диабет 1-го типа
650		4	\|a инсулин гларгин
650		4	\|a инсулин глулизин
650		4	\|a инсулин детемир
650		4	\|a инсулин аспарт
650		4	\|a инсулин деглудек
650		4	\|a фармакоэкономика
650		4	\|a моделирование осложнений
653		0	\|a Medical technology
653		0	\|a Pharmacy and materia medica
700	0		\|a A. A. Kurilev \|e verfasserin \|4 aut
700	0		\|a Y. E. Balikina \|e verfasserin \|4 aut
700	0		\|a M. A. Proskurin \|e verfasserin \|4 aut
773	0	8	\|i In \|t Качественная клиническая практика \|d Izdatelstvo OKI, 2020 \|g (2022), 1, Seite 4-16 \|w (DE-627)1760591807 \|x 26188473 \|7 nnns
773	1	8	\|g year:2022 \|g number:1 \|g pages:4-16
856	4	0	\|u https://doi.org/10.37489/2588-0519-2022-1-4-16 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/864afcbe094147a9beab69ad5e267701 \|z kostenfrei
856	4	0	\|u https://www.clinvest.ru/jour/article/view/602 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2588-0519 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2618-8473 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|j 2022 \|e 1 \|h 4-16

Indexfelder

author_variant	a s k ask a a k aak y e b yeb m a p map
matchkey_str	article:26188473:2022----::hciiaeooicaatrsiocretaiblsnuiteayceeida
hierarchy_sort_str	2022
callnumber-subject-code	R
publishDate	2022
allfields	10.37489/2588-0519-2022-1-4-16 doi (DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 A. S. Kolbin verfasserin aut The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon. сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica A. A. Kurilev verfasserin aut Y. E. Balikina verfasserin aut M. A. Proskurin verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2022), 1, Seite 4-16 (DE-627)1760591807 26188473 nnns year:2022 number:1 pages:4-16 https://doi.org/10.37489/2588-0519-2022-1-4-16 kostenfrei https://doaj.org/article/864afcbe094147a9beab69ad5e267701 kostenfrei https://www.clinvest.ru/jour/article/view/602 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2022 1 4-16
spelling	10.37489/2588-0519-2022-1-4-16 doi (DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 A. S. Kolbin verfasserin aut The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon. сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica A. A. Kurilev verfasserin aut Y. E. Balikina verfasserin aut M. A. Proskurin verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2022), 1, Seite 4-16 (DE-627)1760591807 26188473 nnns year:2022 number:1 pages:4-16 https://doi.org/10.37489/2588-0519-2022-1-4-16 kostenfrei https://doaj.org/article/864afcbe094147a9beab69ad5e267701 kostenfrei https://www.clinvest.ru/jour/article/view/602 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2022 1 4-16
allfields_unstemmed	10.37489/2588-0519-2022-1-4-16 doi (DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 A. S. Kolbin verfasserin aut The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon. сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica A. A. Kurilev verfasserin aut Y. E. Balikina verfasserin aut M. A. Proskurin verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2022), 1, Seite 4-16 (DE-627)1760591807 26188473 nnns year:2022 number:1 pages:4-16 https://doi.org/10.37489/2588-0519-2022-1-4-16 kostenfrei https://doaj.org/article/864afcbe094147a9beab69ad5e267701 kostenfrei https://www.clinvest.ru/jour/article/view/602 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2022 1 4-16
allfieldsGer	10.37489/2588-0519-2022-1-4-16 doi (DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 A. S. Kolbin verfasserin aut The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon. сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica A. A. Kurilev verfasserin aut Y. E. Balikina verfasserin aut M. A. Proskurin verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2022), 1, Seite 4-16 (DE-627)1760591807 26188473 nnns year:2022 number:1 pages:4-16 https://doi.org/10.37489/2588-0519-2022-1-4-16 kostenfrei https://doaj.org/article/864afcbe094147a9beab69ad5e267701 kostenfrei https://www.clinvest.ru/jour/article/view/602 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2022 1 4-16
allfieldsSound	10.37489/2588-0519-2022-1-4-16 doi (DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701 DE-627 ger DE-627 rakwb rus R855-855.5 RS1-441 A. S. Kolbin verfasserin aut The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon. сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica A. A. Kurilev verfasserin aut Y. E. Balikina verfasserin aut M. A. Proskurin verfasserin aut In Качественная клиническая практика Izdatelstvo OKI, 2020 (2022), 1, Seite 4-16 (DE-627)1760591807 26188473 nnns year:2022 number:1 pages:4-16 https://doi.org/10.37489/2588-0519-2022-1-4-16 kostenfrei https://doaj.org/article/864afcbe094147a9beab69ad5e267701 kostenfrei https://www.clinvest.ru/jour/article/view/602 kostenfrei https://doaj.org/toc/2588-0519 Journal toc kostenfrei https://doaj.org/toc/2618-8473 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2022 1 4-16
language	Russian
source	In Качественная клиническая практика (2022), 1, Seite 4-16 year:2022 number:1 pages:4-16
sourceStr	In Качественная клиническая практика (2022), 1, Seite 4-16 year:2022 number:1 pages:4-16
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений Medical technology Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Качественная клиническая практика
authorswithroles_txt_mv	A. S. Kolbin @@aut@@ A. A. Kurilev @@aut@@ Y. E. Balikina @@aut@@ M. A. Proskurin @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	1760591807
id	DOAJ097193356
language_de	russisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097193356</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2022 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37489/2588-0519-2022-1-4-16</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097193356</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ864afcbe094147a9beab69ad5e267701</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. S. Kolbin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет 1-го типа</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин глулизин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин детемир</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин аспарт</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">моделирование осложнений</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kurilev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Y. E. Balikina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. A. Proskurin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2022), 1, Seite 4-16</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:4-16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37489/2588-0519-2022-1-4-16</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/864afcbe094147a9beab69ad5e267701</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/602</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">4-16</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	A. S. Kolbin
spellingShingle	A. S. Kolbin misc R855-855.5 misc RS1-441 misc сахарный диабет 1-го типа misc инсулин гларгин misc инсулин глулизин misc инсулин детемир misc инсулин аспарт misc инсулин деглудек misc фармакоэкономика misc моделирование осложнений misc Medical technology misc Pharmacy and materia medica The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
authorStr	A. S. Kolbin
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760591807
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R855-855
illustrated	Not Illustrated
issn	26188473
topic_title	R855-855.5 RS1-441 The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults сахарный диабет 1-го типа инсулин гларгин инсулин глулизин инсулин детемир инсулин аспарт инсулин деглудек фармакоэкономика моделирование осложнений
topic	misc R855-855.5 misc RS1-441 misc сахарный диабет 1-го типа misc инсулин гларгин misc инсулин глулизин misc инсулин детемир misc инсулин аспарт misc инсулин деглудек misc фармакоэкономика misc моделирование осложнений misc Medical technology misc Pharmacy and materia medica
topic_unstemmed	misc R855-855.5 misc RS1-441 misc сахарный диабет 1-го типа misc инсулин гларгин misc инсулин глулизин misc инсулин детемир misc инсулин аспарт misc инсулин деглудек misc фармакоэкономика misc моделирование осложнений misc Medical technology misc Pharmacy and materia medica
topic_browse	misc R855-855.5 misc RS1-441 misc сахарный диабет 1-го типа misc инсулин гларгин misc инсулин глулизин misc инсулин детемир misc инсулин аспарт misc инсулин деглудек misc фармакоэкономика misc моделирование осложнений misc Medical technology misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Качественная клиническая практика
hierarchy_parent_id	1760591807
hierarchy_top_title	Качественная клиническая практика
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760591807
title	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
ctrlnum	(DE-627)DOAJ097193356 (DE-599)DOAJ864afcbe094147a9beab69ad5e267701
title_full	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
author_sort	A. S. Kolbin
journal	Качественная клиническая практика
journalStr	Качественная клиническая практика
callnumber-first-code	R
lang_code	rus
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
container_start_page	4
author_browse	A. S. Kolbin A. A. Kurilev Y. E. Balikina M. A. Proskurin
class	R855-855.5 RS1-441
format_se	Elektronische Aufsätze
author-letter	A. S. Kolbin
doi_str_mv	10.37489/2588-0519-2022-1-4-16
author2-role	verfasserin
title_sort	clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
callnumber	R855-855.5
title_auth	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
abstract	Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.
abstractGer	Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.
abstract_unstemmed	Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults
url	https://doi.org/10.37489/2588-0519-2022-1-4-16 https://doaj.org/article/864afcbe094147a9beab69ad5e267701 https://www.clinvest.ru/jour/article/view/602 https://doaj.org/toc/2588-0519 https://doaj.org/toc/2618-8473
remote_bool	true
author2	A. A. Kurilev Y. E. Balikina M. A. Proskurin
author2Str	A. A. Kurilev Y. E. Balikina M. A. Proskurin
ppnlink	1760591807
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.37489/2588-0519-2022-1-4-16
callnumber-a	R855-855.5
up_date	2024-07-04T00:10:35.372Z
_version_	1803605073329127424
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ097193356</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413174536.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2022 xx \|\|\|\|\|o 00\| \|\|rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.37489/2588-0519-2022-1-4-16</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ097193356</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ864afcbe094147a9beab69ad5e267701</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">A. S. Kolbin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Basis-bolus insulin therapy is a cornerstone of Diabetes Mellitus type 1 (DM1T) control. Basal insulin analogs — glargine 300 U/ml (iGla 300), glargine 100 U/ml (iGla 100), detemir (iDet) degludec (iDeg), — as well as prandial insulins — glulisine (iGlu), aspart (iAsp) and lispro — are used widely during last 10–15 years. Aim. Evaluation of a comparative economic efficacy of the different basis-bolus schemes of insulin therapy in DM1T in adults. Materials and methods. Analysis has been performed for the following schemes: iGla 300 + iGlu, iGla 100 + iGlu, iDet+iAsp, iDeg+iAsp from Govt position based on modelling of the efficacy for 5 years. Data regarding probability of complications based on glycated hemoglobin (HbA1c) reduction for human insulin treatment and insulin analogs were taken into modelling. Direct medical costs were calculated for insulins, complications, hypoglycemic including severe events. Sensitivity analysis has been performed for validation of the received results. Results: Insulin analogs have economic advantages in compare with human insulins for DM1T control for 6.5 years. They could reduce expenditures in 1.89 times. iGla 300 + iGlu and iDeg+iGlu reduced HbA1c more effective among analogs and hypo events were more rare also (35.0 episodes/patient/year), including severe (0.57 and 0.70 episodes/patient/ year accordingly) vs iGla 100 + iGlu and iDet+iAsp (37.8 and 39.9 episodes/patient/year and 1.10 and 1.21 episodes/patient/ year for severe accordingly). Calculated direct medical costs were less for iGla 300 + iGlu, after that were following iGla 100 + iGlu, iDet+iAsp and last (highest) were expenditures for iDeg+iAsp. Conclusion. Created model prognoses complications of DM1T depending on schemes of insulin therapy and calculates of direct costs. iGla 300 + iGlu has economic advantages vs iGla100 + iGlu, iDet+iAsp and iDeg+iAsp in DM1T control during 5 years horizon.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">сахарный диабет 1-го типа</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин гларгин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин глулизин</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин детемир</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин аспарт</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">инсулин деглудек</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">фармакоэкономика</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">моделирование осложнений</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A. A. Kurilev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Y. E. Balikina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">M. A. Proskurin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Качественная клиническая практика</subfield><subfield code="d">Izdatelstvo OKI, 2020</subfield><subfield code="g">(2022), 1, Seite 4-16</subfield><subfield code="w">(DE-627)1760591807</subfield><subfield code="x">26188473</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2022</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:4-16</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.37489/2588-0519-2022-1-4-16</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/864afcbe094147a9beab69ad5e267701</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.clinvest.ru/jour/article/view/602</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2588-0519</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2618-8473</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2022</subfield><subfield code="e">1</subfield><subfield code="h">4-16</subfield></datafield></record></collection>
score	7.400646

Nicht das Richtige dabei?

Schreiben Sie uns!

The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?